All In Biotech

Free tool

FAERS Monitor: Bkemv

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming BLA 761333 or its brand name (Bkemv, Eculizumab-Aeeb). Reports on generic versions are filed under their own applications.

Reports

11

Serious

8

73% of reports

Hospitalization

5

Death reported

2

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • death2
  • arthropathy1
  • fatigue1
  • gallbladder operation1
  • gastrointestinal haemorrhage1
  • hospitalisation1
  • muscle discomfort1
  • off label use1
  • premature baby1
  • product use in unapproved indication1
  • rash1
  • renal transplant1
  • septic shock1
  • tendon discomfort1
  • unevaluable event1

Reports by year received

View as table
YearReports
20251
202610

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,054,148 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
tendon discomfort12538.5391.2633
muscle discomfort12441.3376.2609
renal transplant1529.581.7131
gallbladder operation1472.672.9117
premature baby163.59.815
septic shock144.06.810
arthropathy134.45.38
unevaluable event125.33.95
gastrointestinal haemorrhage122.93.55
hospitalisation112.41.92
product use in unapproved indication17.71.21
death24.41.33
rash14.40.70
fatigue12.50.40
off label use12.20.30

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.